BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 27, 2002
View Archived Issues
ISTA’s Stock Slides On Vitrase Missed Primary Endpoint
Wall Street did not look kindly on ISTA Pharmaceuticals’ failure to meet its primary endpoint in two pivotal Phase III studies of Vitrase, a single injection for treating vitreous hemorrhage. (BioWorld Today)
Read More
AVI Financing Garners $22M For Antisense, Cancer Vaccines
Read More
Huntington’s Disease Divulges Perplexities Of Its Horrendous Hallmarks, Inexorable Lethality
Read More
TKT’s Dynepo Gains Approval In Europe; Amgen Fight Goes On
Read More
Bush Unveils Planned NIH, Surgeon General Nominations
Read More
Other News To Note
Read More